Carmolex's advanced solutions/platform is poised to deliver Sanofi in Germany with a diverse set of high-quality chemotypes, pre-clinical, low molecular weight hits against biologically relevant PPIs; with a hit rate of at least 20%.
(PRWeb October 18, 2012)
Read the full story at http://www.prweb.com/releases/2012/10/prweb10016134.htm
